Aktuelles

Frauenklinik erfolgreich auf dem jährlichen Forschungstag der Medizinischen Fakultät

Einen mit jeweils 350 € dotierten Posterpreis erhielten Alina Edinger (sFLT1-induced preeclampsia and a high-caloric diet increase the risk of a metabolic syndrome only in male offspring) und Cathérine Zündorf (A cell-free DNA prognostic indicator for pathological response and recurrence in early triple negative breast cancer) beim diesjährigen Forschungstag der Medizinischen Fakultät. Auch Anne Rohloff stellte die ersten Daten ihrer Promotionsarbeit vor (Analysis of bone marrow disseminated tumor cells in hormone receptor positive/HER2-negative breast cancer patients with long versus short time survival). Zudem stellte auch Fenglian Yang (fehlt auf dem Bild) ihre Promotionsarbeit vor (Effect of the immunomodulatory-factor B7-H4 on umbilical cord blood-derived endothelial colony-forming cells (ECFC) and its role in the pathogenesis of preeclampsia).

Bild von links: Prof. Dr. Alexandra Gellhaus, Alina Edinger, Catherine Zündorf, Prof. Dr. Kasimir-Bauer, Anne Rohloff

Am 16.06.23 wurde die PostDoc aus dem Labor der Frauenklinik Frau Dr. rer. nat. Corinna Keup für die Genome Medicine Publikation (DOI: 10.1186/s13073-021-00902-1) mit dem Top Young Scientist Best Paper Award der medizinische Fakultät ausgezeichnet.

Posterpreis beim Forschungstag 2023 für die ELAN Medizindoktorandin Lou Hecker, die ihre experimentelle Doktorarbeit in unserem Labor unter Betreuung von Dr. C. Keup durchführt. Wir gratulieren.

1. Hagenbeck C, Kössendrup J, Soff J, Thangarajah F, Scholten N. Pelvic floor-related sexual functioning in the first 24 months postpartum: Findings of a large cross-sectional study. Acta Obstet Gynecol Scand. 2025 Jan;104(1):203-214. doi: 10.1111/aogs.14990. Epub 2024 Oct 25. PMID: 39460381.

2. González-Conde M, Yáñez C, Abuín C, Keup C, Lestón RL, Palacios P, Curiel T, Cueva J, Rodríguez C, Carmona M, Cortegoso A, García-Caballero T, Muinelo-Romay L, Kasimir-Bauer S, López-López R, Costa C. Gene expression analysis in circulating tumour cells to determine resistance to CDK4/6 inhibitors plus endocrine therapy in HR+/HER2- advanced breast cancer patients. J Transl Med. 2025 Apr 4;23(1):400. doi: 10.1186/s12967-025-06374-w. PMID: 40186268

3. Moukas S, Dohn M, Kimmig R, Tewes M, Kolberg HC, Kasimir-Bauer S, Keup C. Do thymidine kinase 1 (TK1) plasma concentration and activity play a role in therapy management of metastatic breast cancer patients treated with CDK4/6 inhibitors? Sci Rep. 2025 Mar 25;15(1):10347. doi: 10.1038/s41598-025-95114-7.PMID:40133412.

4. Ludwig S, Pfleiderer M, Püchel J, Amir-Kabirian C, Jeschke J, Ratiu D, Eichler C, Morgenstern B, Mallmann P, Radosa J, Thangarajah F. Comparison of Open Abdominal and Laparoscopic Bilateral Uterosacral Ligament Replacement: A One-Year Follow-Up Study. J Clin Med. 2025 Mar 11;14(6):1880. doi: 10.3390/jcm14061880. PMID: 40142688.

5. Adams J, Wingels A, Amir-Kabirian C, Jeschke JK, Gesemann L, Eser B, Lenz C, Morgenstern B, Thangarajah F. The Predictive Value of Preoperative Histological Risk Factors in Early Cervical Cancer. J Clin Med. 2025 May 8;14(10):3277. doi: 10.3390/jcm14103277. PMID: 4042927. 

6. Bhatt A, Stepanyan A, Moran BJ, Chi D, Fotopoulou C, Baumgartner JM, Bakrin N, Deraco M, Ferron G, Kepenekian V, Kusamura S, Lavoue V, Al Niaimi A, Arjona-Sanchez A, Sehouli J, Sukumar V, Turaga K, Villeneuve L, Planchamp F, Zapardiel Gutiérrez I, Brennan DJ, Glehen O; PSOGI-ESGO-ISSPP Collaborators. Peritonectomy procedures for peritoneal surface malignancies: PSOGI-ESGO-ISSPP Lyon consensus. Br J Surg. 2025 May 31;112(6): znaf112. doi: 10.1093/bjs/znaf112. PMID: 40560098. 

7. Lenz C, Lyu SI, Mallmann P, Morgenstern B, Thangarajah F. Impact of Surgical Margin Distance on Oncologic Outcomes in Vulvar Squamous Cell Carcinoma. J Clin Med. 2025 Jun 8;14(12):4057. doi: 10.3390/jcm14124057. PMID: 40565804.

8. Moukas S, Kuningas K, Helle M, Kokko L, Kimmig R, Kasimir-Bauer S, Buderath P, Huhtinen K. CA-125 glycovariant assays enhance diagnostic sensitivity in the detection of epithelial ovarian cancer. Clin Chem Lab Med. 2025 Sep 18;64(1):185-193. doi: 10.1515/cclm-2025-0561. Print 2026 Jan 27. PMID: 40967743. 

9. Kolberg HC, Schumacher J, Erber R, Braun M, Fasching PA, Grischke EM, Schem C, Lux MP, Deryal M, Hoffmann O, Heinrich B, Kunz G, Lübbe K, Krabisch P, Hartmann A, Räth P, Kasimir-Bauer S, Kolberg-Liedtke C. Atezolizumab monotherapy window preceding combined neoadjuvant chemo- and immune therapy in triple negative breast cancer (TNBC) – the neoMono trial. Clin Cancer Res. 2025 Nov 14;31(22):4680-4687. doi: 10.1158/1078-0432.CCR-25-1288.PMID:40932365. 

10. Nicolò E*, Reduzzi C*, Pierga JY, Gazzaniga P, Stoecklein N, Denninghoff V, Rothwell D, De Bono J, Marchetti D, Lianidou E, Riethdorf S, Generali D, Hofman P, Gerratana L, Kuhn P, Thiery JP, Ignatiadis M, Bidard FC, Lucci A, Kasimir-Bauer S, Serrano MJ, Cristofanilli M. International expert consensus on the clinical integration of circulating tumor cells in solid tumors. Eur J Cancer. 2025 Dec 9; 231:116050. doi: 10.1016/j.ejca.2025.116050. Epub 2025 Oct 20. PMID: 41172567. 

11. Salmon C, Neves RPL, Stöcklein NH, Liffers ST, Siveke J, Kuhlmann JD, Wimberger P, Buderath P, Kimmig R, Kasimir-Bauer S. Phenotypic and genotypic characterization of single circulating tumor cells in the follow-up of high-grade serous ovarian cancer. Mol Oncol, in press.

AACR (American Association for Cancer Research: 

Tolios A, Vardas V, Bittner AK, Hoffmann O, Kimmig R, Kasimir-Bauer S, *Kallergi G*. Expression of the Prostate Specific Membrane Antigen (PSMA) and Programmed Death-Ligand 1 (PD-L1) on Disseminated Tumor Cells from Early Triple Negative Breast Cancer Patients with Regard to their Clinical Impact. Poster.

ASCO (American Society for Clinical Obncology): 

Moukas SI, Kasimir-Bauer S, Thangarajah F, Bergqvist M, Ritzén H, Kimmig R, Buderath P. Thymidine kinase activity as a prognostic tool in blood samples of primary ovarian cancer patients. eAbstract.

Sachs CH, Hampl M, Gaß P, Dannecker CH, Gallwas J, Thangarajah F, Schochter F, Daum P, Ignatov A, Canzler U, Kalder M, Shaalan W, Hillemanns P, Forner D, Hantschmann P, Schwab R, Bauerschlag D, Reichenbach J, Dimpfl M, Woelber LL. Prognosis of isolated groin recurrence following sentinel lymph node biopsy in primary node-negative vulvar cancer. eAbstract.

EACR (ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH):

Keup C, Tian S, Rulli SJ, Hauch S, Moukas SI, Buderath P, Kimmig R, Kasimir-Bauer S, Thangarajah F. T-cell receptor diversity in buffy coat samples from blood of ovarian, vulvar squamous cell and cervical cancer patients. Poster.

ESMO (European Society for Medical Oncology):

F. Thangarajah, E. Hemmer, S. Kasimir-Bauer, R. Kimmig, J. Siveke, S. Lueong, G. Meyer. Identification of methylation markers in cfDNA of endometrial cancer patients. Poster.

F. Thangarajah, J. Salmanton-Garcia, B. Morgenstern, C. Herpel, J.C. Radosa, A. Anas, B. Aktas, L. Weydandt, J. WIttenborn, P. Meyer-Wilmes, V. Friebe, C. Leidinger, D. Papior, R. Kimmig, B. Eser. Changing trends of lymph node surgery in endometrial cancer: First results of the multicenter E-PEC trial. Poster.

Senologie:

Luther S, Erber R, Kasimir-Bauer S, Hoffmann O, Hartmann S, Hartmann A, Weber F, Keup C, Kimmig R, Kolberg HC, Kolberg-Liedtke C. Vergleich immunologischer Biomarker in Tumorproben von Primärtumoren und Metastasen bei Patientinnen mit metastasiertem Brustkrebs. Unter den Best Abstracts/Vortrag und Poster.

Early Detection Conference / NextGenDx Summit:

Moukas S, Kuningas K, Helle M, Kokko L, Kimmig R, Kasimir-Bauer S, Buderath P, Huhtinen K. CA-125 glycovariant assays enhance diagnostic sensitivity in the detection of epithelial ovarian cancer.

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Eser B, Wang Y, Vansant G, Moukas SI, Kimmig R, Thangarajah F, Kasimir-Bauer S. Comprehensive cytokine and chemokine evaluation in plasma samples of primary, non-metastatic high grade serous ovarian cancer patients to estimate outcome and platinum resistance.

SABCS (San Antonio Breast Cancer Symposium):

Kasimir-Bauer S, Zündorf C, Bittner A-K, Hoffmann O., Kimmig R, Siveke J, Lueong, S. S. A cell-free DNA prognostic indicator for pathological response and recurrence in early triple negative breast cancer. Poster.

GILEAD FÖRDERPROGRAMM

Prof. Dr. Sabine Kasimir-Bauer in Kooperation mit den Hauptprüfern der neoMono Studie, Prof. Dr. Cornelia Kolberg-Liedtke und Prof. Dr. Hans-Christioan Kolberg.

50.000€ Forschungsförderung im Rahmen des GILEAD Förderprogamms: The neoMono Trial: a comprehensive evaluation of circulating immune biomarkers and immune cells to predict tumor response in patients with early triple-negative breast cancer (TNBC).

427.300 € Forschungsförderung Deutsche Krebshilfe “Single disseminated tumor cells in the bone marrow of patients with HR+/HER2- primary breast cancer and long-term survival versus short-term survival: systematic comparative analysis of relevant genomic differences and therapeutic vulnerabilities”. In Kooperation mit Prof. Dr. Nikolas Stoecklein, Klinik für Allgemein, Viszeral-, und Kinderchirurgie; Juniorprofessor Dr. Daniel Doerr, Klinik für Endokrinologie und Diabetologie, beide Heinrich-Heine-Universität Düsseldorf.